MCT-1 oncoprotein accelerates p53 degradation by means of the ubiquitin-dependent proteolysis. Our present data show that induction of MCT-1 increases chromosomal translocations and deregulated G 2 -M checkpoint in response to chemotherapeutic genotoxin. Remarkably, increases in chromosome copy number, multinucleation, and cytokinesis failure are also promoted while MCT-1 is induced in p53-deficient cells. In such a circumstance, the Ras-mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase signaling activity and the expression of metastatic molecules are amplified. Given a p53-silencing background, MCT-1 malignantly transforms normal breast epithelial cells that are satisfactory for stimulating cell migration/ adhesion and tumorigenesis. Detailed analyses of MCT-1 oncogenicity in H1299 p53-null lung cancer cells have shown that ectopically expressed MCT-1 advances xenograft tumorigenicity and angiogenesis, which cannot be completely suppressed by induction of p53. MCT-1 counteracts mutually with p53 at transcriptional levels. Clinical validations confirm that MCT-1 mRNA levels are differentially enriched in comparison between human lung cancer and nontumorigenic tissues. The levels of p53 mRNA are comparatively reduced in a subset of cancer specimens, which highly present MCT-1 mRNA. Our results indicate that synergistic promotions of chromosomal imbalances and oncogenic potency as a result of MCT-1 expression and p53 loss play important roles in tumor development.
Introduction
Cancer pathogenesis is involved in multiple pathways, including inactivation of tumor suppressors, activation of oncogenes, loss of cell differentiation, augmentation of proliferative activity, alteration of hormone receptor status, and increase of metastatic potential (1) . The fine balance between the proto-oncogene function and tumor suppressor activity plays a critical role in regulation of cell growth, cell cycle, and genome stabilization.
Genome aberrations are the hallmark of tumorigenesis. Mitotic checkpoint controls the integrity of chromosome structure (2) (3) (4) (5) . This checkpoint monitors chromosome alignment during metaphase and prevents premature progression through mitosis. Specifically, it can stop mitotic cells from entering anaphase and prohibit chromosomes from moving toward the spindle poles. Proper chromosome segregation is mediated by centrosome cycle, mitotic spindle assembly, and mitotic kinase activation (6) (7) (8) . Errors that are occurring at mitosis can result in mitotic catastrophes, characterized by spindle collapse, multipolar spindles, or cytokinesis failure. Cells that have been encountered with mitotic catastrophes can end up either entering apoptosis or exiting from mitosis with multinucleation or chromosome aberrations. Consequently, the consequential chromosome instability comprises gains or losses of whole chromosome(s) (aneuploidy), translocations, amplifications/deletions, or breaks (9) (10) (11) .
Loss of p53 and hyperactivation of Ras-mitogen-activated protein kinase (MAPK) signaling are implicated in mitotic abnormalities. A deficiency of p53 activity increases in the number of centrosome along with mitotic defects, which leads to chromosome missegregation (12) . In circumstances with little or no functional p53, cells are highly proliferative and nuclear structure rapidly disintegrates during aneuploidy development (13) . Conversely, the p53-proficient cells can better escape from mitotic failures and limit the progress of chromosomal abnormality. Moreover, the mitotic abnormalities coupled with centrosome amplification are induced by Ras-MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)-MAPK activity, in which cells are greatly at risk of genomic instability (14) . Several studies have indicated that activation of MAPK signaling is important for cell transformation and genomic destabilization, which are induced by many oncoproteins, including Mos, Ras, and Raf (15) (16) (17) . Furthermore, activating MAPK (ERK1/2) and H-Ras selectively induces cell invasive phenotypes by enhancing matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2 expression along with increasing invasion and migration abilities (18, 19) . The chromosome instability caused by p53 deficiency can be enhanced to a greater extent by the constitutively active MAPK pathway. This shows that a p53-dependent checkpoint mechanism can effectively prevent the oncogene-mediated MAPK activation and chromosomal instability. In addition, the Ras-MAPK pathway controls cell cycle progression through G 2 phase and affects the critical checkpoint at G 2 -M transition following DNA damage (20) . Thus, oncogenic Ras activation and p53 dysfunction can disrupt genomic integrity via a MAPK-dependent pathway.
The resistances to apoptosis and deregulation of DNA damage checkpoints have been identified in the oncoprotein MCT-1 (multiple copies in a T-cell malignancy)-expressing cells (21) (22) (23) . MCT-1 gene amplification was firstly recognized in the human B-cell and T-cell lymphoma (21) . Ectopic expression of MCT-1 accelerates p53 protein degradation by activation of the AKT-MDM2-proteosome pathway (23) . Genome abnormalities, including chromosome amplification and translocation, are accumulated as MCT-1 reduces p53 activity. MCT-1 is a CDC2/MAPK phospho-oncoprotein involved in cell cycle regulation and DNA damage response (24, 25) . Ectopically expressed MCT-1 activates the cell survival kinase, AKT, and prevents apoptosis induced by serum starvation (21) . Several lines of evidence show that MCT-1 implicates in the translational regulation and tumor development. MCT-1 physically associates with eukaryotic ribosomal complexes (26) , interacts with the cap complex through a RNA-binding motif, and recruits density-regulated protein (DENR/DRP) that contains the SUI1 translation initiation domain (27) . Oncogenic MCT-1 can transform normal breast epithelial cells and enhance xenograft tumorigenicity of MCF-7 breast cancer cells by enhancing invasiveness and decreasing apoptosis (22, 28) . However, MCT-1 tumorigenic effects underlying chromosome aberrations are unknown at present.
Our present data provide direct clinical evidence that MCT-1 mRNA levels are induced in human lung cancers. A p53-silencing cellular background was used to recapitulate the MCT-1 oncogenic strength on promoting chromosome instability and mitotic abnormality. Cell migration and adhesion abilities are enhanced and tumorigenesis is established under a circumstance of MCT-1 expressing/p53 silencing. Further, increasing MCT-1 levels in the p53-null lung cancer cells can advance xenograft tumorigenicity and angiogenesis but that cannot be completely suppressed by induction of p53. These results are the first to show that MCT-1 oncoprotein and p53 reduction collectively enhance chromosome instability and tumorigenicity.
Results

Overexpression of MCT-1 Increases Etoposide-Induced Chromosomal Translocations
In our previous findings, p53 and p21 protein levels are decreased by MCT-1 overexpression in response to bleomycin (BLM) and etoposide (ETO) genotoxicity, and their reductions are attenuated by the inhibition of MEK signaling (23) . To further investigate the role of MCT-1 in response to genotoxic stress, the chemotherapeutic agent ETO was treated with MCT-1-expressing and vector control MCF-10A cells (Fig. 1A) . In comparison with controls, the levels of phospho-Ser 15 p53 and total p53 protein were relatively reduced by ectopically expressed MCT-1 either before ETO (0 hour) or after ETO treatment for 3 hours. In the latter case, the cells were then recultured in an ETO-free medium for 24 hours (3 h→R24). Cytogenetic G-banding analysis subsequently investigated chromosome deviations after ETO-treated cells recovered for 24 hours. Chromosome aberrations were quantified. Table 1 indicated the frequencies of diverse and arbitrary chromosomal abnormalities identified from each sample cohort (n = 30). Chromosomal exchanges, including reciprocal translocations (symmetrical) and dicentric formations (asymmetrical), were predominantly increased under MCT-1 oncogenic stress (63%) compared with control group (30%). Chromosome translocations were evidently increased >2-fold when MCT-1-expressing cells underwent ETO damage, a topoisomerase II inhibitor that is widely used in cancer therapy. As well, chromosome deletions were more frequently observed in MCT-1-expressing cells (20%) than controls (3.3%). Therefore, genome surveillance machinery is impaired in MCT-1 oncogenic stress. High frequency of chromosomal aberrations that are additionally induced by MCT-1 could eventually enhance the tumor progression.
Consistent with MCT-1 induction diminishing p53 protein amounts (Fig. 1A) , a quantitative reverse transcription-PCR (Q-RT-PCR) analysis indicated that MCT-1 significantly reduced p53 mRNA production to 0.4-fold (Fig. 1B) , revealing that MCT-1 also down-regulated p53 at transcriptional stage. To inspect the oncogenic effect of MCT-1 in a p53-deficient background, p53 short hairpin RNA 2 was delivered into MCF-10A cells. As examined by Q-RT-PCR, p53 gene expressions were dramatically knocked down in both control (control-p53) and MCT-1-expressing cells (MCT-1-p53; Fig. 1B) .
To evaluate the possible mechanism of MCT-1 affecting p53 mRNA amounts, the drug that inhibits transcription (actinomycin D, 0.5 μg/mL) was added into culture and then endogenous p53 mRNA decay was monitored for different time periods (0-8 hours). Figure 1C data revealed that p53 mRNA turned over more rapidly under MCT-1 oncogenic stress than that of p53 mRNA that was comparatively stable in controls. This implicates that MCT-1 activity has promoting effect on p53 mRNA turnover.
Ras Signaling Is Stimulated by MCT-1 Expression and p53 Deficiency
As we examined cell proliferation kinase by Raf-1 RBD affinity assay ( Fig. 2A ), the amounts of active H-Ras were really elevated in both p53-deficient control (control-p53) and p53-deficient MCT-1-expressing cells (MCT-1-p53). After normalizing to internal α-actin, the active H-Ras was determined to be a 2.2-fold increase in MCT-1-p53 group and a 1.36-fold enrichment in control-p53 sample (Fig. 2B) . On DNA damage (+ETO), H-Ras activity all significantly reduced but still remained at a 1.46-fold induction in MCT-1-p53 group in comparison with control-p53 sample.
Signaling downstream of H-Ras, the phosphorylation of MEK1/2 and MAPK (ERK1/2) mitogenic cascade was enhanced in both MCT-1 and MCT-1-p53 cells even in response to genotoxin ETO (Fig. 2C ). MEK1/2 phosphorylation in MCT-1-p53 cells moderately decreased, which was consistent with H-Ras deactivation by ETO treatment ( Fig. 2A and B) , under which MAPK phosphorylation remained high. We speculate that H-Ras could be just one of upstream regulators of MEK1/2 and MAPK. MAPK response is followed on H-Ras-MEK signaling activity and that its phospho-alteration could be temporally delayed.
In evaluation of cell proliferation status, equivalent numbers of the p53-silencing cells were cultured in the medium lacking sera and growth factors (−EGF/insulin) for 24 hours. Following incubation in epidermal growth factor (EGF)/insulin-containing medium (+EGF/insulin) for another 36 hours, the accumulative cell numbers (Y axis) was indicated by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Fig. 2D) . In response to growth stimulation, a 1.8-fold increase of MCT-1-p53 cell populations was identified compared with control-p53 set. Therefore, p53 loss, along with MCT-1 induction, profoundly induces H-Ras activity and mitogenesis.
Additional Aneuploidy Is Occurring in MCT-1 Oncogenic Cells with p53 Silencing
Cytogenetic G-banding analysis was again to inspect the chromosomal abnormalities that happened in a p53-deficient background (Fig. 3A) . To our surprise, chromosome copy numbers were increased notably as p53 silenced in MCT-1-expressing cells (MCT-1-p53). However, chromosome amplification did not show in p53-proficient MCF-10A (control) and was infrequently detected in p53-deficient controls (controlp53). Only increasing MCT-1 levels (MCT-1) also cannot dramatically alter chromosome numbers. In analysis of aneuploid and diploid populations after p53 loss, statistics (P < 0.001) were acquired from at least 150 individual metaphase spreads (Table 2) . Comparatively, many more aneuploidies were detected in MCT-1-p53 sample (42.8%) but less recognized in control-p53 group (13.8%).
To study if p53 induction can effectively prevent polyploidy generation, the p53-silencing MCF-10A was further restored with p53 wild-type gene (Table 2) . Surprisingly, ∼98.8% of p53-restored MCT-1-p53 cells (MCT-1-p53 + p53) exhibited aneuploidy but no significant change of aneuploidy populations (15.5%) in p53-restored control-p53 sample (control-p53 + p53). Thus, p53 renovation cannot suppress but it actually advances aneuploidy; this could address the dark side of p53 in progressing chromosome instability under MCT-1-p53 situation.
Flow cytometry analysis further confirmed that the polyploidy frequencies were enhanced significantly in MCT-1-p53 cells (57.2%) compared with control-p53 cells (3.9%; Fig. 3B ). The populations with DNA content more than 4N (polyploidy) were even further increased when MCT-1-p53 cells (96.8%) were treated with the radiomimetic agent BLM for 24 hours. On BLM treatment, however, 47.7% of control-p53 cells were mainly arrested at G 2 -M phase and have no major increase in the polyploidy populations. Inhibition of MEK activity by UO126 (20 μmol/L) during BLM treatment (BLM + UO126) led to a moderate reduction of MCT-1-p53 polyploidy, 96.8% to 80.3%, indicating that UO126 modestly decreased 16.5% of polyploidy development.
In concordance with chromosomal instability, DNA damage-induced γ-H2AX foci that emerged before BLM treatment (−BLM) were particularly found in the MCT-1-p53 group (Fig. 3C ). Along with promoting intrinsic γ-H2AX foci (non-BLM induced), the phospho-MAPK (p44/42) was greatly enhanced ( Fig. 3D) , in which MEK-MAPK signaling coincided with the progress of chromosomal instability in MCT-1-p53. However, no dramatic MAPK phosphorylation has been observed in BLM-untreated MCT-1-expressing cells, which indicated that γ-H2AX formation before BLM treatment could be independent of MAPK activation.
To further confirm the effect of G 2 -M checkpoint in response to BLM, ATM-CHK1-CDC25c signaling activation was examined ( with polyploidy and γ-H2AX increments, particularly in a MCT-1-p53 context.
More Mitotic and Nuclear Abnormalities Happen as MCT-1-Expressing Cells Lose p53
In examination of nuclear morphology and mitotic process, the majority of p53 knockdown controls (control-p53) have completed chromosome segregation followed on chromosomes uniformly aligned on the metaphase plate (Fig. 4A) . However, the cellular chromosomes of p53-silencing MCT-1 cells (MCT-1-p53) aligned at the spindle equator but kept oscillating with low amplitude around the metaphase plate (Fig. 4B) . Desegregated chromosome bridges were observed frequently during anaphase. In analysis of 250 mitotic cells, the percentages of NOTE: From independent experiments, the frequencies of diploidy and aneuploidy were evaluated between p53-deficient control (control-p53), p53-deficient MCT-1 (MCT-1-p53), and p53-deficient cells that reconstituted with p53 gene (control-p53 + p53 and MCT-1-p53 + p53). Abbreviation: ND, not determined. lagging chromosomes in anaphase (mitotic abnormalities) were more detected in MCT-1-p53 (30.97%) than those identified in control-p53 (13.08%; Fig. 4C ). Further probing nuclear integrity in telophase (Fig. 4D) , 17.39% of MCT-1-p53 cells exhibited binuclei, trinuclei, or micronuclei (Fig. 4E) . Conversely, these dramatic nuclear aberrations were barely detected in p53-deficient controls (2.34%). Therefore, abnormal cytokinesis can cause intrinsic alterations of chromosome copy numbers in MCT-1-p53 cells.
To more characterize nuclear activity of the multinucleate cells, the nuclear mitotic apparatus protein (NuMA) was coimmunostained with the endogenous MCT-1 (Fig. 4F) . The numbers of multinucleate MCT-1-p53 cells (top) were greatly increased over control-p53 sample (bottom). We found three interphase nuclei (arrow), a mitotic nucleus with chromosome alignment at the metaphase plate (star), and some micronuclei (asterisk) that were all enclosed within a single cell. This proves that unsynchronized cell cycle progression at different 
MCT-1 Induction and p53 Silence Collectively Promote Tumorigenesis
The metastatic potential was examined in nontumorigenic MCF-10A (Fig. 5A-C) . A 1.96-fold increase in hypoxia-inducible factor-1α (HIF-1α) mRNA was identified in MCT-1-p53 cells (Fig. 5A) . Moreover, MMP-9 mRNA was found to be a 1.99-fold enhancement in MCT-1-p53 circumstance (Fig. 5B) . MCT-1-p53 cells also presented a 1.7-fold amplification in integrin β4 mRNA relative to control-p53 sample (Fig. 5C ). In fact, oncogenic MCT-1 itself has already greatly elevated the transcripts of HIF-1α (1.74-fold), MMP-9 (1.43-fold), and integrin β4 (1.93-fold) in comparison with comparative controls.
Thus, stimulations in HIF-1α, MMP-9, and integrin β gene activation are p53 independent. When cell adhesion ability in a serum-free condition was analyzed with a laminin-coated 96-well plate, MCT-1 and MCT-1-p53 cells showed a dramatic adhesion activity compared with control or control-p53 cells (Fig. 5D) . Moreover, by using 5% horse serum as a chemoattractant, MCT-1 and MCT-1-p53 cells revealed high migratory ability through a Boyden chamber (Fig. 5E) . The elevation of HIF-1α, MMP-9, and integrin-β4 mRNAs has implicated that MCT-1 up-regulates several genes that promote cell survival, angiogenesis, migration, invasion, and adhesion to extracellular matrix proteins (29) (30) (31) .
To examine if putting additional MCT-1 oncogenic effects into the p53-silencing condition are sufficient for tumorigenesis, the p53-silencing MCF-10A cells at cultivated p27 and mRNA levels (C) are highly presented in MCT-1 and MCT-1-p53 cells compared with control and control-p53 cells. In concordance with promoting metastatic potential, MCT-1 and MCT-1-p53 cells adhering to laminin-coated plate (D) and migrating through polyethylene terephthalate-coated membrane (E) increase more than control and control-p53 cells do. F. In comparison with normal lung tissue (set as 1), 10 of 11 (90.9%) human lung tumor specimens show evidence of MCT-1 mRNA increments as determined by Q-RT-PCR. MCT-1 mRNA is rarely detected in the nontumorigenic tissues. G. The levels of p53 mRNA in lung tumors were compared with the relative normal tissues (set as 1). Low p53 mRNA levels are detected in a tumor sample (11), which highly expresses MCT-1. MCT-1 is undetectable in the tumor with p53 abundance (1). Columns, mean from three different assays; bars, SD. p38 were s.c. injected into nude mice. Symptoms of tumor development were only found in 25% of xenografts, which were injected with the late passage of MCT-1-p53 cells (p38; Table 3 ). On the contrary, no sign of tumor development was detected in the mice inoculated with MCT-1-expressing or p53-silencing control cells. This shows that genomic and mitotic aberrations that accumulated in MCT-1 overexpression/p53 loss are enough for malignancy and tumorigenesis.
To obtain direct clinical evidence, 11 pairs of non-small cell lung cancer tissue along with adjacent nonneoplastic lung tissues were examined. Among them, four samples were squamous cell carcinoma (4, 5, 10, 11) and eight specimens were adenocarcinoma (1-3, 6-9), respectively. All of them had done EGF receptor (EGFR) mutation analysis, and four of the eight adenocarcinoma tumor tissues had EGFR mutations (1, 6, 8, 12) . Q-RT-PCR analysis indicated that MCT-1 gene was differentially induced in nearly all human lung cancer samples (90.9%) in comparison with relative nontumorigenic lung tissues that expressed extremely low levels of MCT-1 (Fig. 5F ).
In an attempt to find the correspondence between MCT-1 and p53 presentations, p53 mRNA levels were analyzed in lung cancer samples in parallel with their comparative normal tissues (Fig. 5G) . MCT-1 mRNA presentation was greatly amplified in a lung tumor that has comparatively lower amounts of p53 mRNA (11) . In contrast with that, two of cancer samples (1, 5) presented low MCT-1 mRNA levels but have high amount of p53 transcripts. These clinical data reveal that MCT-1 status could play an important role in the etiology of human lung cancer.
MCT-1 Induction Promotes Tumor Growth in a p53-Null Background
To recapitulate whether MCT-1 tumorigenic outcomes can be augmented in p53-null lung cancer cells, the vector control H1299 (control/H1299) and MCT-1-expressing H1299 (MCT-1/H1299) were s.c. injected into nude mice. Consequently, larger tumors with more neovascularization emerged in MCT-1/H1299 xenografts than those in control/H1299 xenograft tumors (Fig. 6A) . A 20-fold increase in tumor weights was found in MCT-1/H1299 xenografts compared with control/H1299 xenografts. The incidence of tumors that developed from MCT-1/H1299 was 4-fold higher than from control/H1299 (Table 4) . Hemoglobin amounts in these tumors were measured by the QuantiChrom hemoglobin assay. Compared with the hemoglobin standard and normalized with tumor weights, MCT-1/H1299 tumors have a 10-fold increment in hemoglobin quantities than control/H1299 tumors. Angiogenic effect was further characterized by CD31 immunohistochemical analysis that corresponded to microvessel density. The data show that MCT-1/H1299 tumors have more than 2.5 times increase in vascular counts relative to those control/H1299 tumors.
MCT-1 mRNA levels were further evaluated among normal and tumor tissues from nude mice by RT-PCR analysis (Supplementary Fig. S1 ). The internal 18S rRNA levels were constitutively expressed among samples (denoted with asterisks). MCT-1 transcripts (indicated with arrows) were particularly elevated in MCT-1/H1299 tumors (M1 and M2) but undetectable in normal tissues and control/H1299 tumors (C1 and C2). Detailed quantitative analysis indicated that the xenograft tumors that emerged from MCT-1/H1299 presented ∼20-fold MCT-1 mRNA levels in comparison with control/H1299 xenograft tumors (Fig. 6C) . Consistent with angiogenesis stimulation, both H-Ras and HIF-1α mRNA levels were significantly enriched in MCT-1/H1299 xenograft tumors as assessed with Q-RT-PCR analysis ( Supplementary  Fig. S2 ). These also correspond with the enhanced H-Ras signaling, proliferation, and migration/adhesion ability observed in MCF-10A cells with MCT-1 expressing/p53 silencing (Figs. 2 and 5D and E).
Knock-in p53 Gene Cannot Completely Suppress MCT-1 Tumorigenic Effects
To examine if the exogenous p53 can functionally compromise MCT-1 tumorigenic activity, H1299 cells that were primarily transfected with pLXSN vector or MCT-1 oncogene were further introduced with pLHCX vector or wild-type p53 gene. Similar to Fig. 1C data, p53 mRNA was in a 0.4-fold reduction in MCT-1 + p53 cells compared with control + p53 sample (Fig. 6D) .
Subsequently, the p53-reconstituted H1299 cells (MCT-1 + p53 and control + p53) were s.c. injected into nude mice. Unexpectedly, the ectopic MCT-1 + p53 H1299-injected mice still developed larger tumors (4.3-fold increase) contiguous with more hemoglobin amounts (2.3-fold increase) than those evolving from the control + p53 cells (Table 5 ). In comparison with Table 4 data, p53 restoration certainly reduced the extent of tumor burdens and hemoglobin amounts caused by MCT-1/H1299. As reported by Q-RT-PCR study in H1299 tumors, MCT-1 mRNA expression was a 0.4-fold decrease when p53 was renovated (compared between MCT-1 and MCT-1 + p53 xenografts; Fig. 6F ). As well, H1299 cells that ectopically coexpressed MCT-1 and p53 (MCT-1 + p53) have more than a 0.43-fold decrement in MCT-1 mRNA amounts than MCT-1/H1299 (Fig. 6G) . These data suggest that p53 might act as a transcriptional factor that negatively regulates MCT-1 gene expression. Even if p53 induction is capable of suppressing MCT-1 mRNA production, no complete regression in tumorigenicity was found. Therefore, MCT-1 induction enhancing H1299 tumorigenicity is not simply because of p53 deletion, but it also synergizes with other p53-independent oncogenic factors. In conclusion, MCT-1 overexpression reinforces tumorigenicity and metastaticity while p53 is missing. 
Discussion
Our previous work has identified that overexpression of MCT-1 significantly reduces p53 function, deregulates DNA damage responses, and increases the incidence of chromosomal abnormalities (22, 23) . We speculate that the oncogenic chromosome aberrations and tumorigenicity will enormously amplify while putting MCT-1 oncogenic stress in already p53-null or p53-deficient cells, which cannot properly maintain genomic integrity and monitor mitotic checkpoint. Our current data show that MCT-1 counteracts p53 function and further promotes chromosomal translocations, deletions, and amplifications in the absence of p53 (Figs. 1 and 3) .
The hyperactive Ras-MEK-MAPK signaling cascade is related to centrosome amplification, multipolar spindles, and chromosome bridges (14) . Silencing of p53 in MCT-1-inducing cells (MCT-1-p53) can stimulate Ras-MEK-MAPK activity (Fig. 2) , explaining that cell proliferation is less reliant on sera and growth factors. We are exploring every possibility of suppressing the progress of polyploidization induced by oncogenic MCT-1 and p53 deficiency. The polyploidy incidences are reduced moderately by a MEK inhibitor, UO126 (Fig. 3B) , revealing that the MEK signaling is rationally link to chromosomal aberrations that have taken place in a MCT-1-p53 condition. The deregulated cell growth and mitogenesis could produce not only multinuclei but also micronuclei. Micronucleation can further cause the cells to lose large segments or to generate small fragments of chromosomes via breakage of the anaphase bridge. Circumstances of the induction of γ-H2AX foci that represented several intrinsic DNA breaks are incompletely repaired in a MCT-1-p53 context before encountering with the genotoxin (Fig. 3D and E) . Cytokinesis failure also contributes to chromosomal missegregation and increases the risk of micronuclei, giant nuclei, or multinuclei ( Fig. 4B-F) , by which MCT-1 induction further increases aneuploidy in a p53 knockdown background ( Fig. 3A and B ; Table 2 ). Furthermore, unsynchronized cell cycle progression in a multinucleate MCT-1-p53 cell can be another major cause of chromosome inequality (Fig. 4F) . In summary, MCT-1 confers its oncogenic influences by affecting many signaling pathways, which collectively enhance genomic mutations after p53 loss. Significant oncogenic outcomes are not from a single cause but rather from a confluence of factors provoked by MCT-1 oncogenicity and p53 absence. The chromosomal instabilities identified in a MCT-1-p53 situation are the collective consequences of deregulation of DNA damage checkpoints and mitotic aberrations. The fundamental mechanism by which MCT-1 concomitantly exacerbates mitotic and nuclear aberrations is under investigation.
Given a MCT-1-inducing/p53-eradicating circumstance, nontumorigenic MCF-10A cells are malignantly transformed and provide evidence for tumor development in the xenograft nude mice. All these in vitro and in vivo findings show for the first time that MCT-1 induction, along with p53 deficiency, is sufficient for provoking tumorigenesis in the mammals (Table 3) . MCT-1 overexpression itself may be not only directly oncogenic but could also induce a constellation of invasive and metastatic factors (e.g., HIF-1α, MMP-9, and integrin β4) by its transcriptional or translational regulation function. The enhancing H-Ras gene expression followed by an extremely active Ras-MEK-MAPK signaling cascade reinforces tumorigenic outcomes and angiogenic effects (18, 19, 32) . Oncogenic MCT-1 participates in stimulating the Ras-MEK-MAPK cascade ( Fig. 2A-C) as well activates HIF-1α, MMP-9, and integrin β4 gene expression (Fig. 5A-C) , which are overexpressed in diverse malignancies. These also speak to MCT-1-promoting abilities in the cell migration and invasion ( Fig. 5D and E) .
Ras/Raf/MAPK signaling cascade has a biochemical link with p53 transcription and p53 activity. Ras inhibition increases p53 mRNA levels, indicative of a Ras-dependent mechanism that regulates p53 transcriptional activation (33) . Because the MEK inhibitor (UO126) can partly attenuate p53 and p21 reductions (23) , this suggests that MCT-1 could deregulate p53 transcription by constitutively activating Ras-Raf-MAPK. Our data indicate that by escalating MCT-1 levels in a p53-null background (H1299) that carried chromosomal inequality and oncogenic mutations, the tumorigenicity of MCT-1 is manifestly reinforced. As tumor growth and angiogenesis are synergistically promoted in MCT-1/H1299 xenografts ( Fig. 6A ; Table 4 ), these could relate to stimulation in H-Ras and HIF-1α (Supplementary Fig. S2 ) and provide in vivo confirmation for MCT-1 oncogenicity predominantly in a p53-null background. Our data also show that by means of p53 gene transferring cannot totally repress MCT-1/H1299 (p53 null) tumorigenicity (compare Fig.  6B with Fig. 6E ; Tables 4 and 5 ). Previous studies have indicated that MCT-1-expressing MCF-7 (p53 proficient) also can promote angiogenesis in xenografting tumorigenicity (28) . Reduction of MCT-1 mRNA is identified in p53-reconstituted H1299 cells and xenograft tumors (Fig. 6F and G) , implying that p53 could antagonize mutually with MCT-1 at a transcriptional level. Reciprocally, MCT-1 overexpression works against p53 function and promotes advanced tumorigenicity in the absence of p53, besides that MCT-1 has other tumorigenic functions that are p53 independent.
A very important finding is that increasing MCT-1 transcripts are identified in the majority of human lung cancer specimens examined at this point (Fig. 5F ), implicating that MCT-1 hyperactivation could associate with the cancer susceptibility. The clinical evidence might disclose the counteracting relation between MCT-1 and p53, in which p53 mRNA levels are comparatively low in a sample that highly expresses MCT-1 (Fig. 5G, 11) . Vice versa, MCT-1 is barely detectable in the tumor sample that is p53 abundant (Fig. 5G, 1) . Our current findings also open some intriguing questions, including how MCT-1 can induce tumorigenesis in a p53-null or in a p53-preserve backgrounds, how does MCT-1 stimulate metastatic potential after p53 deficiency, whether oncogenic MCT-1 and p53 loss synergistically up-regulate the metastatic molecules via a posttranscriptional mechanism as recently reported (34) , and whether oncogenic MCT-1 turns tumor suppressor p53 into the dark side of contributing to tumorigenesis (35) . Advance knowledge in MCT-1 function could illuminate the fundamental mechanism of tumorigenesis and help the design of therapeutic target.
Materials and Methods
Antibodies and Reagents
Antibodies recognizing p53 and actin were acquired from Santa Cruz Biotechnology; phospho-CHK1 (Ser 317 ), phospho-CDC25c (Ser 216 ), phospho-p53 (Ser 15 ), phospho-MAPK (p42/p44), and ERK1/2 were from Cell Signaling Technology; phospho-ATM (Ser 1981 ), γ-H2AX, and H-Ras were from Upstate Biotechnology; α-actin or β-actin was from Abcam; and V5 epitope antibody was from Invitrogen. BLM, ETO, and actinomycin D were acquired from Sigma and UO126 was from Cell Signaling Technology.
MCT-1 Overexpression and p53 Knockdown
MCF-10A cells were transfected with pLXSN MCT-1-V5 using viral supernatants collected from PT67 cells and subsequently transfected with pMKO.1 puro p53 short hairpin RNA 2 (Addgene) using Lipofectamine 2000 (Invitrogen). Four cohorts of transfectants (mass culture) were established, including pLXSN-control (control), MCT-1-overexpressing cells (MCT-1), p53-silencing control (control-p53), and MCT-1-expressing/p53-silencing cells (MCT-1-p53). These cells were cultured in DMEM/F12 medium containing 5% horse serum, 20 ng/mL EGF, 10 μg/mL insulin, 0.5 μg/mL hydrocortisone, 100 ng/mL cholera toxin, 100 units/mL penicillin, 100 μg/mL streptomycin, and selection antibiotic (100 μg/mL G418 or 0.5 μg/mL puromycin).
Raf-1 RBD Affinity Assay for Active H-Ras
Exponentially growing MCF-10A cells were cultured with 40 μmol/L ETO for 1 h. Active Ras was isolated on Raf-1 RBD-glutathione agarose according to the manufacturer's instructions (Upstate Biotechnology). Cells were extracted with magnesium-containing lysis buffer and precleared with glutathione beads. Raf-1 RBD agarose (5-10 μg of protein) was incubated with 500 μg to 1 mg of lysates and gently rotated at 4°C for 30 min. The beads were washed thrice with magnesiumcontaining lysis buffer. Raf-1 RBD-associated H-Ras was resolved by SDS-PAGE and immunoblotting.
Tumor Xenografts and Hemoglobin Assay
Non-small cell lung cancer cells (H1299) were overexpressed in MCT-1 and cultured as previously described (23) . Eight-week-old female BALB/c nude mice were injected with MCT-1-expressing H1299 or the vector control H1299. Each mouse was injected with 2 × 10 6 cells suspended in 100 μL RPMI 1640 at both s.c. sites. The p53-silencing MCF-10A cells (2 × 10 6 ) were premixed with equal volume of ice-cold BD Matrigel matrix (10 mg/mL; BD Biosciences) before injecting into nude mice. When tumor size had reached approximately 4 to 6 mm, tumors were resected, weighted, and processed for immunohistochemistry or Q-RT-PCR analysis.
Hemoglobin amounts in the tumors were measured by spectrophotometry using the QuantiChrom hemoglobin assay kit (BioAssay Systems). Tumors excised from mice were immediately washed with PBS, immersed in 1 mL sterile distilled water, and incubated on an orbital shaker for 10 min at room temperature. Following centrifugation at 14,000 rpm for 15 min, 50 μL of the supernatant were incubated with 200 μL of the hemoglobin assay reagent for 5 min at room temperature. Hemoglobin concentrations were calculated based on absorbance absorption at 400 nm. Compared with the standard, hemoglobin quantities were indicated as absorbance sample/ absorbance standard = mg/g wet tissue.
Human Lung Cancer Tissues and Quantitative Real-time RT-PCR Analysis
Eleven pairs of surgically resected fresh frozen non-small cell lung cancer tissues along with adjacent nonneoplastic lung tissues were obtained from the tissue bank of Chang-Gung Memorial Hospital (Taoyuan, Taiwan), which were approved by the Institutional Review Board of Chang-Gung Memorial Hospital.
Total RNA was extracted from the tissues using Trizol reagent (Invitrogen). cDNA was synthesized from 2 μg of total RNA using an oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and SuperScript II reverse transcriptase (Invitrogen). The Q-RT-PCR was done with nucleotide 61 MCT-1 sense (5′-GAGCGGAAGTAGTCA-GATTT-3′) and nucleotide 431 MCT-1 antisense (5′-TGTTCATGGCATCGGACTAT-3′) primers. Reaction mixtures (20 μL) contained 150 ng cDNA, 2 μmol/L primers, and 1× SYBR Green Master Mix (Applied Biosystems). Reactions were run on the ABI Prism 7900 Fast Real-Time PCR System in triplicate. The reaction was conducted as follows: 95°C for 10 min followed by 45 cycles of a 15-s denaturing at 95°C and 1-min annealing at 60°C. The RT-PCR products were resolved by 2% agarose gel electrophoresis and stained with ethidium bromide. The mRNA levels were calculated. Cycle threshold (ΔC t ) = C t target gene (MCT-1) − C t endogenous control (18S rRNA gene). H-Ras, HIF-1α, MMP-9, integrin β4, and p53 specific primers were respectively designed by Primer Express software to ensure a single 69-, 76-, 54-, 114-, and 72-bp amplicon. The probes were labeled with NFQ (quencher) and FAM (reporter) and synthesized by Integrated DNA Technologies (Applied Biosystems). The standard Taqman assays were analyzed after normalizing to β-actin.
Cell Proliferation MTT Assay
MCF-10A cells were subcultured in the basal DMEM/F12 medium without growth factors and horse sera. Fifty microliters of cell suspension (1 × 10 5 cells/mL) were seeded into each 96-well plate and incubated at 37°C for 24 h. After starvation, cells were supplemented with 50 μL DMEM/F12 medium containing growth factors (40 ng/mL EGF and 20 μg/mL insulin) for 36 h. Cell Proliferation Kit I (Roche) was used as follows: cells
